

Date: 28 June 2023

Subject: Update on SKYCLARYS® (omaveloxolone) 50 mg capsules Availability

Dear FA Community,

With the availability of SKYCLARYS® (omaveloxolone) 50 mg capsules, we expect that the exclusive specialty pharmacy (Biologics) can begin shipping product to patients with a prescription and verified insurance coverage. Patients with insurance approval may have already been contacted by a Biologics pharmacist to initiate their onboarding call, which includes drug counseling for SKYCLARYS. Now that product is available, Biologics will conduct a second patient outreach to collect any required copayment and coordinate shipment directly to an address of the patient's choosing.

Product shipping for patients with an insurance approved prescription will depend on the pharmacy's ability to connect with the patient over the phone. This onboarding call is required before drug can be shipped. Patients should be prepared to answer calls from Biologics. Depending on the patient's phone carrier, the call may show as coming from the number 1-800-850-4306. Once this step is completed for the first shipment, patients will be contacted for all refills approximately two weeks before the prescription runs out.

Any patient with a SKYCLARYS prescription who does not yet have insurance approval will receive communication from Reata REACH, the patient support service hub. Reata REACH will inform patients when they have their insurance determination and are able to fill the prescription.

No action is necessary from patients with prescriptions, other than to look out for calls from Reata REACH or Biologics.

We appreciate the patience through this process and encourage patients to please contact Reata REACH at 1-844-987-3224 (1-844-98-REACH). For more information, patients can also visit www.ReataReach.com.

Sincerely,

Sara Johnson Davis

Senior Director, Patient Advocacy, Medical Affairs

Reata Pharmaceuticals, Inc.

© 2023 Reata Pharmaceuticals, Inc. All rights reserved. SKYCLARYS and REATA are registered trademarks of Reata Pharmaceuticals, Inc